Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia.
作者信息
Hotta Katsuyuki, Kiura Katsuyuki, Takigawa Nagio, Matsuo Keitaro, Tabata Masahiro, Fujiwara Yoshiro, Tanimoto Mitsune
出版信息
J Clin Oncol. 2008 Dec 10;26(35):5826-7; author reply 5827. doi: 10.1200/JCO.2008.19.5685. Epub 2008 Nov 10.
PMID:19001344
Abstract
摘要
相似文献
1
Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia.
J Clin Oncol. 2008 Dec 10;26(35):5826-7; author reply 5827. doi: 10.1200/JCO.2008.19.5685. Epub 2008 Nov 10.
2
[Side effects of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)].
Nihon Rinsho. 2015 Feb;73 Suppl 2:245-9.
3
First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?携带激活型表皮生长因子受体突变的晚期非小细胞肺癌的一线治疗：表皮生长因子受体酪氨酸激酶抑制剂还是化疗？
Curr Opin Oncol. 2011 Mar;23(2):131-2. doi: 10.1097/CCO.0b013e328341ee26.
4
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.第一代和第二代小分子人表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌中的胃肠道毒性
Curr Opin Support Palliat Care. 2016 Jun;10(2):152-6. doi: 10.1097/SPC.0000000000000210.
5
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors.对表皮生长因子受体酪氨酸激酶抑制剂的耐药性。
J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1084-5. doi: 10.1097/01.JTO.0000361760.11575.54.
6
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.一名表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者在接受EGFR酪氨酸激酶抑制剂治疗后转变为鳞状细胞癌表型。
J Clin Pathol. 2015 Apr;68(4):320-1. doi: 10.1136/jclinpath-2015-202866. Epub 2015 Feb 6.
7
Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?达可替尼用于肺癌治疗：来自过去时代的“失落一代”表皮生长因子受体酪氨酸激酶抑制剂？
Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015.
8
Afatinib (Gilotrif) for advanced non-small cell lung cancer.阿法替尼（吉泰瑞）用于治疗晚期非小细胞肺癌。
Med Lett Drugs Ther. 2015 May 25;57(1469):e82-3.
9
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
10
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.表皮生长因子受体突变和间变性淋巴瘤激酶阳性非小细胞肺癌的辅助治疗：现有数据和未来前景。
Lung Cancer. 2015 Oct;90(1):1-7. doi: 10.1016/j.lungcan.2015.07.016. Epub 2015 Jul 30.
引用本文的文献
1
Chronic myeloid leukemia during osimertinib treatment in a non-small cell lung cancer patient: A case report.一名非小细胞肺癌患者在奥希替尼治疗期间发生慢性髓系白血病：病例报告
Heliyon. 2024 Aug 29;10(17):e37040. doi: 10.1016/j.heliyon.2024.e37040. eCollection 2024 Sep 15.
2
Therapy-related myeloid leukemia during erlotinib treatment in a non-small cell lung cancer patient: A case report.一名非小细胞肺癌患者在厄洛替尼治疗期间发生的治疗相关髓系白血病：病例报告
World J Clin Cases. 2021 Aug 26;9(24):7205-7211. doi: 10.12998/wjcc.v9.i24.7205.
3
Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.对系统治疗的混合反应揭示了非小细胞肺癌患者潜在的基因异质性和较差的生存率。
Oncologist. 2017 Jan;22(1):61-69. doi: 10.1634/theoncologist.2016-0150.
Zotero 插件